Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus CAPEOX and bevacizumab versus CAPEOX and bevacizumab for first-line conversion therapy in unresectable MSS colorectal liver metastases
ChiCTR2300072773Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab, bevacizumab, oxaliplatin and capecitabine in colorectal cancer (CRC) and colorectal cancer liver metastasis (CRLM) (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: objective response rate. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
sintilimabbevacizumaboxaliplatincapecitabine
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on ChiCTR2300072773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072773.